Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Immunotherapy

Targeted Therapies and Immunotherapies Approved for Patients with Non–Small-Cell Lung Cancer in 2020-2022
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival. Read More ›

Recent Progress in Small-Cell Lung Cancer Therapy
Lung cancer is divided into 2 main categories that require different therapies. Most of the new therapies are for the common type, but recently, immunotherapy has shown promise for this less common lung cancer type. Read More ›

Beyond Chemotherapy: Immunotherapy Offers a New Treatment Option for Women with Endometrial Cancer

Imfinzi Approved for Advanced or Metastatic Biliary Tract Cancer

Immunotherapy Side Effects: Symptoms and Management
Many side effects of immunotherapy can be effectively managed with early detection and intervention. It is important that patients with cancer and their caregivers know what symptoms to look for. Read More ›

Jemperli a New Immunotherapy Approved for All Patients with dMMR Solid Tumors
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options. Read More ›

Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›

The Immunotherapy Surge
In this special issue focused on immunotherapy, we take a deep dive into this exciting type of treatment, highlighting the role of genetic testing and new developments in lung, skin, and bladder cancer in improving patient outcomes. Read More ›

Molecular Profiling and Immunotherapy Offered Me New Hope After Stage IV Lung Cancer Diagnosis
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer. Read More ›

Molecular Profiling Is Making Cancer Treatment Personal
Tim Dorius, MD, explains the role of molecular profiling in relation to immunotherapy, and how oncologists can now look at the genetic makeup of a tumor to identify specific mutations or other biomarkers. Read More ›

Page 1 of 7